← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
The Broad Institute, Inc
$30,760,949
Total funding
27
Grants
Funding over time
peak $9.6M · FY2009–25$10M$7.5M$5M$2.5M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
DOD$28,044,966 · 17
USDA$2,116,223 · 8
NASA$599,761 · 2
By mechanism
—$30,760,949 · 27
Investigators at The Broad Institute, Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
'MULTIDIMENSIONAL CHEMOGENIC CONTROL OF CRISPR- NUCLEASES IN CELLS AND ORGANISMS'$7,319,225
· FY2017 · Department of the Navy
DETECTION OF NUCLEIC ACID SIGNATURES OF GENETIC ENGINEERING$4,577,503
· FY2018 · Department of the Navy
PRECLINICAL DEVELOPMENT OF AN ANTIMALARIAL AGENT WITH A NEW MECHANISM OF ACTION$3,099,575
· FY2018 · Defense Health Agency
BROAD-MIT CENTER FOR HIGH-THROUGHPUT SYNTHETIC BIOLOGY$2,690,706
· FY2014 · Defense Advanced Research Projects Agency
THE PURPOSE OF THIS COOPERATIVE AGREEMENT IS TO FUND RESEARCH IN SUPPORT TO BTO IN THE AMOUNT OF 750,000 ON CONTRACT HR0011-17-2-0049.$2,250,000
· FY2017 · Defense Advanced Research Projects Agency
PRECLINICAL DEVELOPMENT OF A NOVEL ANTIMALARIAL AGENT$1,997,826
· FY2016 · Department of the Army
ELUCIDATING THE CLONALITY OF SOMATIC MUTATIONS IN VASCULAR MALFORMATIONS ARISING IN HEREDITARY HEMORRHAGIC TELANGIECTASIA$1,380,553
· FY2025 · Defense Health Agency
TARGETING KIT IN CHROMOPHOBE RCC WITH MONO- AND BI-PARATOPIC ANTIBODY DRUG CONJUGATES$987,600
· FY2024 · Defense Health Agency
GENOME SEQUENCING OF WHEAT STRIPE RUST AND COMPARATIVE GENOMICS OF PUCCINIA SPP.$985,000
· FY2009 · National Institute of Food and Agriculture
DEFINING SIGNALING PATHWAYS AND EFFECTIVE COMBINATION THERAPY TO IMPROVE OUTCOMES FOR PATIENTS WITH FGFR2-DRIVEN BILIARY CANCER$936,000
· FY2022 · Department of the Army
WHEAT LEAF RUST GENOME SEQUENCING AND COMPARATIVE RESOURCES FOR RUST FUNGI$847,031
· FY2011 · National Institute of Food and Agriculture
MECHANISMS OF HYPEROXIA INDUCED CELL DEATH$689,181
· FY2023 · Department of the Navy
BACKGROUND: THE CENTRAL DOGMA IS QUINTESSENTIAL TO LIFE ON EARTH ENABLING LIVING SYSTEMS TO CARRY OUT INFORMATION PROCESSING METABOLISM REPRODUCTION AND HOMEOSTASIS. RNA A UNIQUELY INFORMATION-DENSE AND CATALYTIC BIOMOLECULE SITS AT THE CENTER OF THIS REQUIREMENT FOR LIFE IN ALL KNOWN BIOLOGICAL SYSTEMS AND MIGHT HAVE BEEN RESPONSIBLE FOR THE TRANSITION FROM SIMPLE CHEMICAL TO COMPLEX BIOLOGICAL SYSTEMS. AMONG RNA COMPONENTS DEFINING THE CENTRAL DOGMA THERE IS PERHAPS NONE MORE IMPORTANT THAN THE RIBOSOME WHICH SERVES AS A CELLULAR NEXUS OF INFORMATION TRANSFER RESOURCE ALLOCATION AND GROWTH MODULATION. CONSERVATION OF THE RIBOSOME IS USED TO TRACE EVOLUTIONARY TRAJECTORIES ACROSS THE TREE OF LIFE FROM LUCA YET THERE IS LITTLE EVIDENCE TO SUPPORT RRNA-BASED PHYLOGENETIC RECONSTRUCTIONS OF INTERMEDIATE VERSIONS OF THE TRANSLATIONAL APPARATUS. METHODOLOGIES THAT ENABLE THE RECONSTRUCTION AND EXPERIMENTAL VALIDATION OF ANCESTRAL RIBOSOME INTERMEDIATES ALONG PLAUSIBLE EVOLUTIONARY TRAJECTORIES TO ITS CURRENT FORM WOULD TRANSFORM OUR UNDERSTANDING OF THE ORIGIN OF LIFE ON EARTH ELUCIDATE THE EVOLUTION OF MODERN RIBOSOMES AND POTENTIALLY INFORM ROUTES FOR TRANSLATION ELSEWHERE IN THE COSMOS. MAJOR GOALS: HISTORICALLY ORIGINS-OF-LIFE RESEARCHERS HAVE FOCUSED ON ABOTTOM-UP APPROACH TO THE PREDICTION OF INTERMEDIATE PRE-BIOTIC BIOMOLECULES IN WHICH ARTIFICIAL CHEMICAL SYSTEMS ARE CONSTRUCTED IN ATTEMPTS TO RECREATE CONDITIONS ON THE EARLY EARTH. CONVERSELY ATOP-DOWN APPROACH IN WHICH EXISTING BIOLOGICAL SYSTEMS ARE REDUCED TO THEIR UNDERLYING COMPONENTS WOULD INFORM THE FUNCTIONAL AND MINIMAL COMPONENTS THAT MAY HAVE EXISTED IN A PREBIOTIC ERA. WE PROPOSE TO TAKE A TOP-DOWN APPROACH TO THE MINIMIZATION OF THE RIBOSOME WITHIN THE FUNCTIONALITY-RELEVANT ENVIRONMENT OF THE CELL. SUCH A COMBINATION OF THEORETICAL AND EXPERIMENTAL ANALYSIS WOULD INFORM THE CHEMICAL FUNCTIONALITY DEFINING TRANSLATION. HOWEVER STUDIES AIMED AT PROBING CELLULAR TRANSLATION HAVE RARELY ACCESSED SUCH A DETAILED UNDERSTANDING OF THE MINIMAL REQUIREMENTS FOR TRANSLATION. THIS IS A DIRECT CONSEQUENCE OF DIFFICULTIES ASSOCIATED WITH RIBOSOME MANIPULATION IN VIVO AS TRANSLATION CANNOT BE EASILY UNCOUPLED FROM CELLULAR VIABILITY OR OVERALL FITNESS. THUS OUR PROPOSED WORK REQUIRES THE REMOVAL OF CONFOUNDING ATTRIBUTES REGULATING CELLULAR VIABILITY THAT MAY BE INCORRECTLY ASSUMED TO INFLUENCE THE REQUIREMENTS FOR THIS BIOMOLECULAR ACTIVITY. SPECIFIC AIMS: TO ACHIEVE THESE GOALS WE PROPOSE TO INTEGRATE SYNTHETIC BIOLOGY COMPUTATIONAL AND PHYLOGENETIC RRNA ANALYSIS AND EVOLUTIONARY PRINCIPLES TO INFORM PLAUSIBLE AND TESTABLE MINIMAL RIBOSOME INTERMEDIATES EN ROUTE TO THE EXTANT TRANSLATION MACHINERY OF THE CELL: 1. AIM I: CONSTRUCTION OF A DEFINED SENSOR THAT RECAPITULATES RIBOSOMAL ACTIVITY IN E. COLI AS A MODULAR AND ORTHOGONAL PLATFORM BY UNCOUPLING TRANSLATION FROM HOST VIABILITY. 2. AIM II: APPLICATION OF THIS SENSOR PLATFORM TOWARDS THE IN VIVO ANALYSIS OF THE EFFECTS OF RRNA TRUNCATIONS AND/OR MUTATIONS ON TRANSLATION OF A SINGULAR SYNTHETIC MRNA TRANSCRIPT. 3. AIM III: OPTIMIZATION OF MINIMIZED RRNA VARIANTS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) TO REVEAL COMPENSATORY MUTATIONS THAT ENHANCE ACTIVITY. CONCLUSION: OUR PROPOSED WORK AIMS TO OVERCOME CHALLENGES ASSOCIATED WITH RIBOSOMAL MANIPULATION IN VIVO AND PROVIDES AN INNOVATIVE FRAMEWORK FOR THE DERIVATION OF MINIMIZED RIBOSOMES. WHILE THIS IS AN AMBITIOUS INTEGRATION OF EVOLUTIONARY PRINCIPLES AND SYNTHETIC BIOLOGY TO ILLUMINATE THE ORIGINS OF TRANSLATION WE HOPE THAT IT WILL SUPPLEMENT THE EXISTING (BUT INCOMPLETE) MOLECULAR RECORD OF RIBOSOMAL EVOLUTION AND PROVIDE NOVEL INSIGHT INTO POTENTIAL PROTO-RIBOSOMAL GENOTYPES AND PHENOTYPES. OUR PROPOSED WORK WOULD MARK THE FIRST MAJOR EFFORT TO MINIMIZE THIS COMPLEX MACROMOLECULAR MACHINE PROVIDING EXPERIMENTAL EVIDENCE FOR A POTENTIAL ROUTE TOWARDS THE DEVELOPMENT OF LIFE OF EARTH.$593,761
· FY2020 · National Aeronautics and Space Administration
TARGETING THE ZER1 UBIQUITIN LIGASE FOR THE TREATMENT OF HPV+ PENILE, ANAL, AND VULVAR CANCERS$499,600
· FY2025 · Defense Health Agency
GENOME DYNAMICS OF HOST SPECIFICITY IN THE FUSARIM OXYSPORUM SPECIES COMPLEX$498,400
· FY2011 · National Institute of Food and Agriculture
THE ROLE OF MAP KINASE PATHWAY ACTIVATION IN THE TREATMENT OF NRAS-MUTANT AND THERAPY-RESISTANT BRAF-MUTANT MELANOMA$311,862
· FY2022 · Defense Health Agency
MECHANISMS OF UVEAL MELANOMA SENSITIVITY TO VELCRIN TREATMENT$311,669
· FY2022 · Defense Health Agency
EXAMINING THE ROLE OF CHROMOSOMAL INSTABILITY IN BREAST CANCER EVOLUTION$290,957
· FY2016 · Department of the Army
TARGETING FGFR2 FUSIONS WITH NOVEL ANTIBODY THERAPEUTICS IN CHOLANGIOCARCINOMA$238,529
· FY2020 · Defense Health Agency
OVERCOMING CHEMORESISTANCE IN OVARIAN CANCER BY TARGETING A NOVEL LIPID HYDROPEROXIDASE PATHWAY$232,747
· FY2018 · Department of the Army